After massive rallies delivered by the growth part of my portfolio, it became imbalanced as the share of defensive plays decreased in relative terms. Therefore, I am adding Johnson & Johnson (NYSE: JNJ ) stock to my portfolio andAs an investor who started my path five years ago with my own capital, I represent a blend of hands on experience and academic background in corporate finance. Due to my relatively young age I thrive on discovering long-duration growth opportunities and actively seek out opportuniti ...

The most recent trading session ended with Johnson & Johnson (JNJ) standing at $150.47, reflecting a -1.24% shift from the previouse trading day's closing. This change lagged the S&P 500's 0.61% gain on the day. Elsewhere, the Dow gained 0.69%, while the tech-heavy Nasdaq added 1.31%.The the stock of world's biggest maker of health care products has fallen by 3.78% in the past month, lagging the Medical sector's loss of 1.45% and the S&P 500's gain of 5.79%.Investors will be eagerly watching for the perform ...

Johnson & Johnson (JNJ) announced that it has filed two supplemental biologics license applications (sBLA) seeking expanded use of its drug Tremfya in pediatric patients.While one sBLA seeks approval of Tremfya for treating children 6 years and older with moderate-to-severe plaque psoriasis (PsO), the other one is for children 5 years of age and older with active juvenile psoriatic arthritis (jPsA).Tremfya, an IL-23 inhibitor, is already approved to treat certain adult patients with plaque psoriasis and act ...

Applications filed for TREMFYA® to treat children with moderate to severe plaque psoriasis and active juvenile psoriatic arthritis  SPRING HOUSE, Pa., Dec. 2, 2024 /PRNewswire/ -- Johnson & Johnson today announced the submission of two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) seeking approval of TREMFYA® (guselkumab) for the treatment of children 6 years and older with moderate-to-severe plaque psoriasis (PsO) and children 5 years of age and older wi ...

BRIDGEWATER, N.J. and BENGALURU, India, Dec. 2, 2024 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today that the U.S. Food and Drug Administration (FDA) has approved YESINTEK™ (Ustekinumab-kfce), a biosimilar to the reference product, Stelara® (Ustekinumab). YESINTEK™, a monoclonal antibody, is approved for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic a ...

文章核心观点 - 将最大的股息投资组合比例分配给强生公司（Johnson & Johnson）可以有效降低投资组合的波动性，作为战略防御措施 [1] 投资策略 - 专注于构建旨在通过股息产生额外收入的投资组合，重点关注具有显著竞争优势和强大财务状况的公司，以提供有吸引力的股息收益率和股息增长 [1] - 通过结合高股息收益率和股息增长公司，逐步减少对整个股市波动的依赖 [1] - 建议在投资组合中纳入低贝塔系数的公司，以进一步降低整体风险水平 [1] 投资组合构建 - 投资组合通常由ETF和个别公司混合组成，强调广泛的多元化和风险降低 [1] - 投资组合的构建过程经过精心策划，优先考虑总回报，包括资本收益和股息，而不仅仅是孤立地关注股息 [1] 多元化策略 - 帮助投资者在各个行业和部门实现多元化投资组合，以最小化投资组合波动性和降低风险 [1]

Checking a company's vital signs before investing in its stock for dividend income is essential. If the underlying company isn't financially healthy, its dividend probably won't last very long.That won't be a problem with Johnson & Johnson (JNJ 0.39%) and Medtronic (MDT -0.53%). They're healthy companies that should continue to pay durable dividends in the decades ahead, making them great income investments. As healthy as it getsJohnson & Johnson is among the world's healthiest companies. The healthcare gia ...

文章核心观点 - 强生公司（Johnson & Johnson, JNJ）已向美国食品药品监督管理局（FDA）提交监管文件，寻求批准其重磅免疫学药物Tremfya（guselkumab）用于溃疡性结肠炎（UC）的皮下（SC）诱导治疗方案 [1][2] 公司动态 - 强生公司计划为UC患者提供更便捷的Tremfya治疗方案，相比静脉注射（IV）剂量，皮下剂量更易管理且更舒适 [3] - 如果此次监管申请获批，Tremfya将成为首个在UC适应症中提供IV或SC诱导治疗选择的IL-23抑制剂 [3] - 此次申请基于III期ASTRO研究的数据，该研究在第12周达到了临床缓解的主要终点，并实现了所有次要终点 [4] - Tremfya已在多个国家（包括美国和欧洲）获批用于银屑病和活动性银屑病关节炎（PsA）适应症 [5] - 强生公司还于6月提交了Tremfya用于中度至重度活动性克罗恩病（CD）的标签扩展申请 [6] - Tremfya是强生免疫学药物组合中的重要药物，2024年前九个月销售额达到27亿美元，同比增长22%，预计将成为50亿美元的产品 [9] 行业背景 - 溃疡性结肠炎（UC）和克罗恩病（CD）是两种主要的炎症性肠病（IBD），近年来由于遗传因素、环境因素和生活方式的改变，其患病率有所上升 [6][7] - 免疫系统异常、更高的诊断率、早期诊断的重视以及发达国家的有利报销政策推动了IBD治疗的需求 [7] - IBD市场竞争激烈，主要参与者包括艾伯维（AbbVie, ABBV）和礼来（Eli Lilly, LLY） [10][11] - 艾伯维的免疫学产品Skyrizi和Rinvoq表现出色，支持了其未来几年的收入增长 [10] - 礼来公司去年获得了FDA对Omvoh用于UC适应症的批准，并正在寻求其用于CD适应症的标签扩展 [11]

Whether you prefer growth stocks, value stocks, dividend stocks, or a mixture of investments in your portfolio, price should only be one factor you consider when determining which businesses to add.Dividends can be a great way to increase your returns with time while giving you extra capital to reinvest or keep in your portfolio. These kinds of stocks can be found across many different sectors and industries.If you're looking for two top dividend stocks to consider for your portfolio and have $500 available ...

Join iREIT® on Alpha today to get the most in-depth research that includes REITs, mREIT, Preferreds, BDCs, MLPs, ETFs, Builders, and Asset Managers. Our iREIT® Tracker provides data on over 250 tickers with our quality scores, buy targets, and trim targets.When it comes to Dividend Elite’s, at the top of the hierarchy are Dividend Kings. Dividend Kings are defined as companies that have increased their dividend for 50+ consecutive years.Brad, along with HOYA Capital, lead the investing group iREIT®+HOYA Cap ...